PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
There is increasing evidence linking a fetal and early neonatal systemic inflammatory
response syndrome to the subsequent development of bronchopulmonary dysplasia (BPD) and white
matter injury (WMI) in very preterm infants. Babies with evidence of adrenal insufficiency
early in life may not be able to control the inflammatory response and are thereby more
likely to develop BPD than babies who do not show such evidence of inflammation. We designed
a randomized controlled trial to test the hypothesis whether very preterm babies at high-risk
of BPD, treated with low doses of HC during the first 10 days of life, are more likely to
survive without BPD at 36 weeks of post-menstrual age (PMA), compared to babies treated with
placebo.